Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2020; 5: 548-560.
Published: 17th November 2020
Authors: Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y et al.
Some 156 patients were included. After median follow-up of 55.9 months, relapse-free survival was 43.4 per cent after active treatment versus 21.7 per cent in controls (hazard ratio 0.49, 95 per cent confidence interval 0.34 to 0.72, P=0.0031).Pubmed Link
You may also be interested in
Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels. A randomized controlled trial. Ann Surg 2018: 268: 943-954.
Authors: Huang G, Li P-P, Lau WY, Pan Z-Y, Zhao L-H, Wang Z-G et al.
Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017; 109. doi: 10.1093/jnci/djx015.
Authors: Ruers T, Van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA et al.
Fibrin sealant patch (TachoSil) vs oxidized regenerated cellulose patch (Surgicel Original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg 2012; 222: 261-268.
Authors: Genyk Y, Kato T, Pomposelli JJ, Wright Jr JK, Sher LS, Tetens V et al.
Fibrin sealant with polyglycolic acid felt vs fibrinogen-based collagen fleece at the liver cut surface for prevention of postoperative bile leakage and hemorrhage: a prospective, randomized, controlled study. J Am Coll Surg 2016; 222: 59-64.
Authors: Kobayashi S, Takeda Y, Nakahira S, Tsujie M, Shimizu J, Miyamoto A et al.
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg 2015; 261: 56-66.
Authors: Huang G, Lau WY, Wang Z-G, Pan Z-Y, Yuan S-X, Feng S et al. et al.
Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (<1cm): a prospective randomized study. J Am Coll Surg 2014; 218: 381-392.
Authors: Yu W, Wang W, Rong W, Wang L, Xu Q, Wu F et al. et al.
Adjuvant hepatic intra-arterial iodine 131- lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg 2013; 37: 1356-1361.
Authors: Chung AY, Ooi LL, Machin D, Tan SB, Goh BK, Wong JS et al. et al.
Radiofrequency ablation with or without transcatheter chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31: 426-432.
Authors: Peng Z-W, Zhang Y-J, Chen M-S, Xu L, Lian H-L, Lin X-J et al. et al.
Effects of pentoxifylline on liver regeneration: a double blinded, randomized clinical trial in 101 patients undergoing major liver resection. Ann Surg 2010; 252: 813-822.
Authors: Petrowsky H, Breitenstein S, Slankamenac K, Vetter D, Lechmann K, Heinrich S et al. et al.
A prospective randomized controlled trial of preoperative transarterial chemoembolisation for resectable large hepatocellular carcinoma Ann Surg 2009; 249: 195-202
Authors: Zhou W-P, Lai ECH, Li A-J, Fu S-Y, Zhou J-Ppan Z-y et al
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for respectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
Authors: Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al.